<DOC>
	<DOC>NCT01389700</DOC>
	<brief_summary>Primary Objective: - To determine the pharmacokinetics (PK) of a single intravenous (IV) dose of SAR279356 administered to intensive care unit (ICU) patients on mechanical ventilation Secondary Objectives: - To determine the safety and tolerability of SAR279356 - To evaluate the pharmacodynamics (PD) and immunogenicity of SAR279356 - Exploratory efficacy of SAR279356 on prevention of bacterial infections</brief_summary>
	<brief_title>Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients</brief_title>
	<detailed_description>Total study duration (from screening to last follow-up visit) is 91 days break down as follows: - Screening: 1 day prior to dosing; - Treatment period: one IV injection on Day 1; - Follow-up period: 90 days</detailed_description>
	<criteria>Inclusion criteria : ICU patients on mechanical ventilation at the time of randomization Patients or legally authorized representative (LAR) giving written informed consent. Exclusion criteria: Patients &lt;18 years of age; Documented Pseudomonas infection or colonization in the last 30 days; Immunocompromised patients Hypersensitivity to the study drug and/or to prior therapy with monoclonal antibodies; Patient who has taken other investigational drugs or prohibited therapy for this study within 1 month or 5 halflives, whichever is longer; Patient or LAR who withdraws consent during the screening (starting from signed informed consent form); Acute liver injury related criteria at the time of study entry: Pregnant or breastfeeding women The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>